Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew D. Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. , 397(10276), DOI: https://doi.org/10.1016/s0140-6736(21)00237-3.
Article147 days ago[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew D. Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. , 397(10276), DOI: https://doi.org/10.1016/s0140-6736(21)00237-3.
Article147 days ago[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew D. Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. , 397(10276), DOI: https://doi.org/10.1016/s0140-6736(21)00237-3.
Article147 days ago[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew D. Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. , 397(10276), DOI: https://doi.org/10.1016/s0140-6736(21)00237-3.
Article147 days ago177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Alison Yan Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis (2021). 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).. , 39(6_suppl), DOI: https://doi.org/10.1200/jco.2021.39.6_suppl.6.
Article147 days ago